Abstract
Background: Different 3-aroylpropionic acids and dihydropyrimidine hydrazine derivatives were condensed together to yield a series of dihydropyrimidine and pyridazinone hybrids (5a-u).
Objective: This was done in order to develop therapeutic agents for the treatment of breast cancer with improved Cycloxygenase-2 (COX-2) selectivity. In-vitro anticancer evaluation for these compounds was done against human breast cancer cell lines (MCF-7, MDA-MB-231) and normal human keratinocytes (HaCaT).
Conclusion: Amongst all the developed analogs, compound 5l emerged as the most potent agent against both these cell lines with IC50 values of 3.43 and 2.56 µM respectively. The synthesized compounds were also evaluated for COX-2 selectivity. To observe the binding pattern of the compounds with COX-2, a docking study was performed using PDB ID: 1CX2.
Keywords: Anticancer agent, breast cancer, COX-2 inhibitors, cyanopyrimidne, hybrid, pyridazinone.
Graphical Abstract
Mini-Reviews in Medicinal Chemistry
Title:Synthesis of Hybrids of Dihydropyrimidine and Pyridazinone as potential Anti-Breast Cancer Agents
Volume: 18 Issue: 4
Author(s): Wasim Akhtar, Garima Verma, Mohemmed Faraz Khan, Mohammad Shaquiquzzaman, Arpana Rana, Tarique Anwer, Mymoona Akhter and M. Mumtaz Alam*
Affiliation:
- Drug Design and Medicinal Chemistry Lab, Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Jamia Hamdard, New Delhi 110062,India
Keywords: Anticancer agent, breast cancer, COX-2 inhibitors, cyanopyrimidne, hybrid, pyridazinone.
Abstract: Background: Different 3-aroylpropionic acids and dihydropyrimidine hydrazine derivatives were condensed together to yield a series of dihydropyrimidine and pyridazinone hybrids (5a-u).
Objective: This was done in order to develop therapeutic agents for the treatment of breast cancer with improved Cycloxygenase-2 (COX-2) selectivity. In-vitro anticancer evaluation for these compounds was done against human breast cancer cell lines (MCF-7, MDA-MB-231) and normal human keratinocytes (HaCaT).
Conclusion: Amongst all the developed analogs, compound 5l emerged as the most potent agent against both these cell lines with IC50 values of 3.43 and 2.56 µM respectively. The synthesized compounds were also evaluated for COX-2 selectivity. To observe the binding pattern of the compounds with COX-2, a docking study was performed using PDB ID: 1CX2.
Export Options
About this article
Cite this article as:
Akhtar Wasim, Verma Garima, Khan Faraz Mohemmed, Shaquiquzzaman Mohammad, Rana Arpana, Anwer Tarique, Akhter Mymoona and Alam Mumtaz M.*, Synthesis of Hybrids of Dihydropyrimidine and Pyridazinone as potential Anti-Breast Cancer Agents, Mini-Reviews in Medicinal Chemistry 2018; 18 (4) . https://dx.doi.org/10.2174/1389557517666170220153456
DOI https://dx.doi.org/10.2174/1389557517666170220153456 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nitric Oxide-Derived Oxidants with a Focus on Peroxynitrite: Molecular Targets,Cellular Responses and Therapeutic Implications
Current Pharmaceutical Design Gold Nanoparticles - Synthesis and Applications in Cancer Management
Recent Patents on Materials Science New Folate-Modified Human Serum Albumin Conjugated to Cationic Lipid Carriers for Dual Targeting of Mitoxantrone against Breast Cancer
Current Pharmaceutical Biotechnology Clinical Significance of Thiopurine S-Methyltransferase Gene Polymorphisms
Current Pharmacogenomics A Mild and Convenient Semi-Synthesis of Docetaxel from 10-Deacetyl Baccatin III
Letters in Organic Chemistry Focusing on the Influenza Virus Polymerase Complex: Recent Progress in Drug Discovery and Assay Development
Current Medicinal Chemistry Parp Inhibitors for the Treatment of Ovarian Cancer
Current Cancer Drug Targets Antagonism by Bioactive Polyphenols Against Inflammation: A Systematic View
Inflammation & Allergy - Drug Targets (Discontinued) Non-Genotoxic p53-Activators and their Significance as Antitumor Therapy of Future
Current Medicinal Chemistry Prediction of Cancer Rescue p53 Mutants In Silico Using Naïve Bayes Learning Methodology
Protein & Peptide Letters The Repurposing of Old Drugs or Unsuccessful Lead Compounds by in Silico Approaches: New Advances and Perspectives
Current Topics in Medicinal Chemistry Targeting SREBP-1-driven Lipid Metabolism to Treat Cancer
Current Pharmaceutical Design Oncogenic Signaling Pathways Activated by RON Receptor Tyrosine Kinase
Current Cancer Drug Targets Clinicopathological Significance of Long Non-Coding RNA <i>GHET1</i> in Human Cancers: A Meta-Analysis
Current Pharmaceutical Biotechnology Novel Agents Targeting Crucial Signalling Pathways in Head and Neck Squamous Cell Carcinoma, HNSCC - Preclinical Development and Data from Clinical Trials
Current Proteomics Anti-Cancer Therapeutic Approaches Based on Intracellular and Extracellular Heat Shock Proteins
Current Medicinal Chemistry Transductional and Transcriptional Targeting of Adenovirus for Clinical Applications
Current Gene Therapy Synthesis and Anticancer Activity of Novel Benzimidazole and Benzothiazole Derivatives against HepG2 Liver Cancer Cells
Medicinal Chemistry MDM2 Increases Drug Resistance in Cancer Cells by Inducing EMT Independent of p53
Current Medicinal Chemistry Selective Estrogen Receptor Modulator Medicinal Chemistry At Merck. A Review
Current Topics in Medicinal Chemistry